|
[225Ac]Ac-FL-261 Clinical Trials
1 actively recruiting trial across 1 location
Pipeline
Phase 1/2: 1
Top Sponsors
- Full-Life Technologies UK Limited1
Indications
- Cholangiocarcinoma1
- Head and Neck Cancer1
- NSCLC1
- Solid Tumor1
- Colorectal Cancer1
Minneapolis, Minnesota1 trial
SumMET: Study of [225Ac]Ac-FL-261 in Participants With Solid Tumors Overexpressing c-MET
Full-Life Technologies Investigational Site
Phase 1/2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.